Alpha Lipoic Acid Blood Glucose Meta-analysis: What the Evidence Says

Quick Answer

Alpha Lipoic Acid Blood Glucose Meta-analysis has 4 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 3 preclinical study, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Experimental data and clinical studies highlight the cardiometabolic changes associated with gonadal aging and reproductive hormones' withdrawal. [Karaflou Maria (2026); evidence level 3]
• Body composition changes with increased fat mass and abdominal fat distribution are associated with insulin resistance and subsequent diabetes in older ages. [Karaflou Maria (2026); evidence level 3]
• This oxidative stress triggers several downstream pathways, including activation of the polyol pathway, increased formation of advanced glycation end products (AGEs), protein kinase C (PKC) activation, and increased hexosamine pathway flux. [Ciubotaru Alin (2026); evidence level 4]
• Both have reached clinical use as over-the-counter supplements, creating an urgent need for critical evidence synthesis, unlike other nutritional agents (e.g., acetyl-L-carnitine and vitamin D), which have either less mechanistic rationale or weaker clinical uptake in DPN. [Ciubotaru Alin (2026); evidence level 4]
• T2DM is primarily characterized by insulin resistance, a pathological condition in which target tissues exhibit a reduced response to insulin, a hormone essential for glucose regulation and uptake (Ahmad et al. ). [Ko Chih‐Yuan (2026); evidence level 4]
• A growing body of evidence supports the notion that oxidative stress and chronic low-grade inflammation are fundamental contributors to the pathogenesis of insulin resistance (Juzbašić et al. ; Rains and Jain ). [Ko Chih‐Yuan (2026); evidence level 4]
• During the study period, 3 patients in the roflumilast group dropped out secondary to non-adherence (n=2) and the development of thyroid cancer (n=1), and 3 patients in the alpha-lipoic acid group also dropped out as a result of non-compliance. [Elsharab Asmaa (2025); evidence level 4]
• Roflumilast treatment reduced FBG from 140 (17) to 118 (11) (P1<0.001), while alpha-lipoic acid reduced FBG from 139 (12) to 123 (10) (P1<0.001). [Elsharab Asmaa (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For alpha lipoic acid blood glucose meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Karaflou Maria (2026). Antioxidants in Menopausal Transition and Male Late-Onset Hypogonadism for the Prevention of Diabetes. DOI: 10.3390/antiox15060659. PMCID: PMC13296154. PMID: 42351965. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13296154/
• Ciubotaru Alin (2026). Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework. DOI: 10.3390/nu18101538. PMCID: PMC13209258. PMID: 42196997. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209258/
• Ko Chih&#8208;Yuan (2026). Alpha&#8208;Lipoic Acid Reduces NLRP3 / ASC Expression and IL &#8208;1&#946; Release in Kupffer Cells and Improves Insulin Signaling in FL83B Hepatocytes Exposed to a Conditioned Medium. DOI: 10.1002/fsn3.71517. PMCID: PMC12868922. PMID: 41648644. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12868922/
• Elsharab Asmaa (2025). Efficacy and Safety of Roflumilast versus Alpha-Lipoic Acid in Type 2 Diabetes with Neuropathy: A Comparative Clinical Study. DOI: 10.2147/DMSO.S548285. PMCID: PMC12621582. PMID: 41256904. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12621582/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.